Efficacy of Palbociclib

Palbociclib has been studied in two major studies of women with HR-positive, HER2-negative breast cancer. In both studies, the main measure of effectiveness was how long patients lived without their disease getting worse (progression-free survival).

The first study involved521 women with metastatic breast cancer whose disease worsened after receiving hormone medication. They were treated with palbociclib and fulvestrant, and the results showed that the women who took palbociclib and fulvestrant lived an average of 11.2 months without worsening of their disease. The second study involved 666 women who had gone through menopause, whose breast cancer had begun to spread and who had not yet received cancer treatment. They received a combination of palbociclib and letrozole, an aromatase inhibitor, and the results showed that women taking palbociclib and letrozole lived an average of 24.8 months without worsening of their disease.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 tablets per box, sold overseas may be around RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by Bangladesh pharmaceutical factory may be around 900 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.